Selank (Tuftsin Analogue)

Selank's Enkephalinase Mechanism

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

Selank's most specifically characterised activity is inhibition of enkephalin-degrading enzymes. Rather than acting at opioid receptors itself, it slows the breakdown of endogenous enkephalins (particularly leu-enkephalin) so the body's own signalling persists longer. This was measured directly on plasma enkephalinase activity.

Key facts

Target
Enkephalin-degrading enzymes
Effect
Extended endogenous enkephalin half-life
Enkephalin most cited
Leu-enkephalin
Not
An opioid receptor ligand
Measured in
Plasma enkephalinase activity
Key references
PMID 11550013, PMID 12432865

What enkephalins are

Enkephalins are short endogenous opioid peptides, met-enkephalin and leu-enkephalin, each five residues,produced from proenkephalin and acting at delta and mu opioid receptors. They are part of the body's own opioid signalling system, and like most signalling peptides they are cleared rapidly by specific peptidases collectively referred to as enkephalinases.

The difference between agonism and degradation inhibition

This distinction is the whole point and it is routinely muddled. An opioid agonist binds the receptor and activates it directly, at whatever concentration is administered, wherever the drug reaches. A degradation inhibitor does not touch the receptor. It allows the endogenous ligand already being released to persist longer, which means the effect is bounded by the body's own release patterns and occurs only where enkephalins are actually being produced.

Research material referenced

Selank 10mg, third-party HPLC tested

Buy Selank · £24.99

What was measured

Work published in the Bulletin of Experimental Biology and Medicine in 2001 reported an inhibitory effect of Selank on enkephalin-degrading enzymes, proposed as a mechanism for its observed activity. A 2002 study in the same journal examined effects on behavioural measures alongside plasma enkephalin-degrading enzyme activity, linking the biochemical observation to a behavioural one.

Why this mechanism is interesting pharmacologically

Modulating a system by slowing clearance of its endogenous ligand is a different intervention from supplying an exogenous agonist. The effect is self-limiting in a way direct agonism is not, because it depends on there being endogenous ligand to preserve. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue, and the comparison is instructive, because that class produces smaller effects than the receptor agonists.

What this does not establish

Enzyme inhibition measured in plasma is a biochemical observation. It does not by itself establish a functional consequence in an organism, and the interventional work here is preclinical. The mechanism is well described; what it produces in humans rests on a clinical literature that is largely Russian-language and difficult to assess independently.

Frequently asked questions

Does Selank act on opioid receptors?

Reported work describes inhibition of enkephalin-degrading enzymes rather than direct receptor binding. It preserves the body's own enkephalins instead of supplying an agonist.

What is an enkephalinase?

A collective term for peptidases that break down enkephalins, clearing them from circulation and from synaptic space.

Is this the same as how DPP-4 inhibitors work?

The logic is analogous (prolong an endogenous peptide rather than supply an analogue) though the peptides and enzymes involved are entirely different.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Selank (Tuftsin Analogue) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.